News
OncClub
All Oncology News
Pipeline Report
Media
Insights
Medical World News
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
The Talk
Conferences
Conference Coverage
Conference Listing
Events
Giants of Cancer Care
PER Events
Scientific Interchanges
State of the Science Summit / IPC
Webinars
Partners
Publications
OncologyLive
Oncology Fellows
Supplements And Featured Publications
All Publications
CME/CE
Resources
Interactive Tools
Learning Modules
Presentations
Sponsored
Subscribe
Print Subscription
eNewsletter

logo
Spotlight
OncLive® National Fellows Forum: Lung Cancer 2023
Join us in Chicago for Giants of Cancer Care®
Specialty
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
OncClub
All Oncology News
Pipeline Report
Insights
Medical World News
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
The Talk
Conference Coverage
Conference Listing
Giants of Cancer Care
PER Events
Scientific Interchanges
State of the Science Summit / IPC
Webinars
Partners
OncologyLive
Oncology Fellows
Supplements And Featured Publications
All Publications
CME/CE
Interactive Tools
Learning Modules
Presentations
Sponsored
Print Subscription
eNewsletter
Advertisement
Urothelial Cancer
| Breast Cancer
| Lung Cancer
| Gastrointestinal Cancer
| Genitourinary Cancers
| Ovarian Cancer
| Prostate Cancer
| Melanoma & Skin Cancer
| Mantle Cell Lymphoma
| Myeloproliferative Neoplasms
| Biosimilars
| Brain Cancer
| Business Management
| CAR T-cell Therapy
| COVID-19
| Chronic Lymphocytic Leukemia
| Colorectal Cancer
| Disparities in Cancer Care
| Global Oncology
| Gynecologic Oncology
| Head & Neck Cancers
| Hematologic Oncology
| Immuno-Oncology
| Multiple Myeloma
| Neoadjuvant HER2+
| Non-Hodgkin Lymphoma
| Oncology Nursing News
| Pediatric Oncology
| Precision Medicine in Oncology®
| Sarcomas/TGCT
| Supportive Care
View All >>
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
  • Business Management
  • CAR T-cell Therapy
  • COVID-19
  • Chronic Lymphocytic Leukemia
  • Colorectal Cancer
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Global Oncology
  • Gynecologic Oncology
  • Head & Neck Cancers
  • Hematologic Oncology
  • Immuno-Oncology
  • Lung Cancer
  • Mantle Cell Lymphoma
  • Melanoma & Skin Cancer
  • Multiple Myeloma
  • Myeloproliferative Neoplasms
  • Neoadjuvant HER2+
  • Non-Hodgkin Lymphoma
  • Oncology Nursing News
  • Ovarian Cancer
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Prostate Cancer
  • Sarcomas/TGCT
  • Supportive Care
  • Urothelial Cancer

SPOTLIGHT -

OncLive® National Fellows Forum: Lung Cancer 2023
| Join us in Chicago for Giants of Cancer Care®

Immune-Related Adverse Effects Linked to Longer Survival With Pembrolizumab in Metastatic Urothelial Carcinoma

May 13, 2022
Lindsay Fischer
Conference|American Urological Association Annual Meeting

Patients with metastatic urothelial carcinoma who received pembrolizumab achieved prolonged median progression-free and overall survival after experiencing an immune-related adverse effect.

Immune-related adverse effects (irAEs) may serve as a prognostic marker for progression-free survival (PFS) and overall survival (OS) in patients with metastatic urothelial carcinoma (mUC) who are receiving pembrolizumab (Keytruda), according to findings presented at the 2022 AUA Annual Meeting.

Ultimately, patients who experienced an irAE while receiving pembrolizumab achieved a median PFS of 28 months (95% CI, 11.7-not reached [NR]) compared with 5.4 months (95% CI, 4.0-8.9) among those who did not experience such an event (P <.0001). Furthermore, the median OS among patients who experienced an irAE was 44.3 months (95% CI, 15.9-44.3; P = .0002) compared with 10.4 months (95% CI, 6.9-19.6) among those who did not (P = .0002).

“PFS was significantly longer in patients with irAEs than [in those] without irAEs,” Kazutaka Nakamura, Department of Urology, Tokiwakai Jyoban Hospital, said in a poster presentation of the findings. “In addition, OS was also significantly longer in patients with irAEs than [in those] without irAEs.”

Study authors noted that the relationship between irAE occurrence and disease prognoses in patients undergoing immune checkpoint inhibition has been observed across various cancer types. Furthermore, multiple studies have reported a positive relationship between irAE incidence and favorable prognoses in patients with mUC receiving pembrolizumab. However, there remains insufficient evidence regarding the prognostic impact of irAEs in this patient population.

Therefore, investigators conducted a retrospective analysis of 95 patients with mUC who received treatment with pembrolizumab as second-line or later-line therapy between January 2018 and February 2022. Patients received pembrolizumab at a dose of either 200 mg every 3 weeks or 400 mg every 6 weeks. Evaluable patients were classified according to their irAE development. Median PFS, OS, overall response rate (ORR), and disease control rate (DCR) were analyzed once the patients began treatment.

Among the 95 evaluable patients, 31 experienced an irAE (32%). Among these patients, a total of 43 irAEs occurred. Notably, there was a significant difference in ECOG performance status greater than 0 between those who did and did not experience an irAE (32% vs 56%, respectively; P =.0282).

At a median follow-up of 15.1 months (interquartile range, 6.1-22.9), 62 patients (65%) had experienced disease progression and 52 (55%) had died.

Overall, univariate and multivariate analysis demonstrated that irAEs is an independent factor contributing to PFS (HR, 0.33; 95% CI, 0.17-0.62; P = .0006). Poor performance status greater than 0 (HR, 2.06; 95% CI, 1.22-3.46; P = .0065) and metastases across multiple organs (HR, 1.75; 95% CI, 1.04-2.94; P = .0343) were also predictive factors for PFS.

Similarly, these factors were also found to be independent factors for OS as well. The hazard ratio for irAEs was 0.32 (95% CI, 0.16-0.66; P = .0018) compared with 2.83 for poor performance status greater than 0 (95% CI, 1.59-5.05; P = .0004), 2.04 for modified Glasgow prognostic score greater than 0 (95% CI, 1.09-3.84; P = .0267), and 1.90 for multiple metastatic organs (95% CI, 1.07-3.39; P = .0288).

Lastly, patients who experienced irAEs achieved significantly higher overall response rates than those who did not experience these events (35% vs 9%, respectively; P = .0019). The difference in disease control rates were significant as well (61% vs 21%, respectively; P = .0002).

“This multi-institutional study showed that [the] presence of irAE[s] was significantly associated with PFS, OS, ORRs, and DCRs in patients [with mUC] treated with pembrolizumab,” the study authors concluded. Moving forward they noted irAE occurrence may be used as a surrogate prognostic factor for pembrolizumab.

Reference

Nakamura K, Ishiyama Y, Nemoto Y, et al. Association between immune-related adverse events and survival of patients with metastatic urothelial carcinoma treated with pembrolizumab. Presented at: 2022 AUA Annual Meeting; May 13-16; New Orleans, LA. Abstract MP03-19. https://bit.ly/3sA2KIA

Related Videos
Petros Grivas, MD, PhD
Andrew Katims, MD, MPH
Sohail Dhanji, MD
Shilpa Gupta, MD
Expert on urothelial carcinoma
Expert on urothelial carcinoma
Experts on urothelial carcinoma
Expert on urothelial carcinoma
Chandler Park, MD, MSc, FACP, co-director, Genitourinary Clinical Trials at Norton Cancer Institute in Louisville, Kentucky
Aaron E. Katz, MD
Related Content

Medicaid Expansion Improves Survival in Pancreatic, Gastric Cancers, Potentially Reducing Disparities

May 25th 2023

FDA Approval Insights: Enfortumab Vedotin Plus Pembrolizumab in Urothelial Carcinoma

April 24th 2023

Pembrolizumab Plus Chemo With or Without Bevacizumab Maintains OS Benefit in Frontline Cervical Cancer

May 25th 2023

FDA Approval Insights: Sacituzumab Govitecan in Urothelial Cancer

July 22nd 2021

Advances Across Urothelial Carcinomas Highlight Need for Shared Decision-making

May 23rd 2023

Adjuvant Abemaciclib Provides Survival Benefit in Chinese Breast Cancer Population

May 18th 2023

Medicaid Expansion Improves Survival in Pancreatic, Gastric Cancers, Potentially Reducing Disparities

May 25th 2023

FDA Approval Insights: Enfortumab Vedotin Plus Pembrolizumab in Urothelial Carcinoma

April 24th 2023

Pembrolizumab Plus Chemo With or Without Bevacizumab Maintains OS Benefit in Frontline Cervical Cancer

May 25th 2023

FDA Approval Insights: Sacituzumab Govitecan in Urothelial Cancer

July 22nd 2021

Advances Across Urothelial Carcinomas Highlight Need for Shared Decision-making

May 23rd 2023

Adjuvant Abemaciclib Provides Survival Benefit in Chinese Breast Cancer Population

May 18th 2023

Medicaid Expansion Improves Survival in Pancreatic, Gastric Cancers, Potentially Reducing Disparities

May 25th 2023

FDA Approval Insights: Enfortumab Vedotin Plus Pembrolizumab in Urothelial Carcinoma

April 24th 2023

Pembrolizumab Plus Chemo With or Without Bevacizumab Maintains OS Benefit in Frontline Cervical Cancer

May 25th 2023

FDA Approval Insights: Sacituzumab Govitecan in Urothelial Cancer

July 22nd 2021

Advances Across Urothelial Carcinomas Highlight Need for Shared Decision-making

May 23rd 2023

Adjuvant Abemaciclib Provides Survival Benefit in Chinese Breast Cancer Population

May 18th 2023
Related Content
Julie R. Gralow, MD, FACP, FASCO

Medicaid Expansion Improves Survival in Pancreatic, Gastric Cancers, Potentially Reducing Disparities

May 25th 2023
Article
Terence Friedlander, MD

FDA Approval Insights: Enfortumab Vedotin Plus Pembrolizumab in Urothelial Carcinoma

April 24th 2023
Podcast
Bradley J. Monk, MD, FACS, FACOG

Pembrolizumab Plus Chemo With or Without Bevacizumab Maintains OS Benefit in Frontline Cervical Cancer

May 25th 2023
Article
FDA Approval Insights: Sacituzumab Govitecan in Urothelial Cancer

FDA Approval Insights: Sacituzumab Govitecan in Urothelial Cancer

July 22nd 2021
Podcast
Petros Grivas, MD, PhD

Advances Across Urothelial Carcinomas Highlight Need for Shared Decision-making

May 23rd 2023
Article
Zhimin Shao, MD

Adjuvant Abemaciclib Provides Survival Benefit in Chinese Breast Cancer Population

May 18th 2023
Article

Latest Conference Coverage

Medicaid Expansion Improves Survival in Pancreatic, Gastric Cancers, Potentially Reducing Disparities

Telephone-Based Weight Loss Program Is Effective for Breast Cancer Survivors

Pembrolizumab Plus Chemo With or Without Bevacizumab Maintains OS Benefit in Frontline Cervical Cancer

Minimally Invasive Distal Pancreatectomy Provides Effective Alternative in Resectable Pancreatic Cancer

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
CancerNetwork.com
CGTlive.com
CureToday.com
OncNursingNews.com
TargetedOnc.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact